Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Wedemeyer

Showing results (31-40 of 151) with videos related to

Pageof 16
Sort By:
Alimentary Pharmacology & Therapeutics|January 13, 2016
Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' replyK Deterding, B Schlevogt, K Port, et al.
Journal of Viral Hepatitis|October 30, 2015
Estimating HCV disease burden - volume 3 (editorial)A Aghemo, G J Dore, A Hatzakis, et al.
Deutsche Medizinische Wochenschrift (1946)|August 24, 2007
[German guidelines on diagnosis and therapy of hepatitis B]H Wedemeyer, M Cornberg, U Protzer, et al.
Der Internist|February 27, 2010
[Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C]I Mederacke, K Wursthorn, H Ho, et al.
Zeitschrift Fur Gastroenterologie|August 18, 2004
[Standard treatment of chronic hepatitis B]M P Manns, W H Caselmann, K H Wiedmann, et al.
Gastroenterology|October 26, 2001
Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse modelH Wedemeyer, S Gagneten, A Davis, et al.
Journal of Virology|November 2, 2001
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cellsH Wedemeyer, E Mizukoshi, A R Davis, et al.
Zeitschrift Fur Gastroenterologie|July 17, 2009
Successful treatment of fulminant hepatitis B during pregnancyA Potthoff, K Rifai, H Wedemeyer, et al.
Deutsche Medizinische Wochenschrift (1946)|May 21, 2008
[Acute hepatitis B: is antiviral therapy indicated? Two case reports]J Girke, H Wedemeyer, J Wiegand, et al.
Zeitschrift Fur Gastroenterologie|June 14, 2003
[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3]M Cornberg, D Hüppe, J Wiegand, et al.
Pageof 16

Showing results (31-40 of 151) with videos related to

Sort By:
Pageof 16
Alimentary Pharmacology & Therapeutics|January 13, 2016
Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authors' replyK Deterding, B Schlevogt, K Port, et al.
Journal of Viral Hepatitis|October 30, 2015
Estimating HCV disease burden - volume 3 (editorial)A Aghemo, G J Dore, A Hatzakis, et al.
Deutsche Medizinische Wochenschrift (1946)|August 24, 2007
[German guidelines on diagnosis and therapy of hepatitis B]H Wedemeyer, M Cornberg, U Protzer, et al.
Der Internist|February 27, 2010
[Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C]I Mederacke, K Wursthorn, H Ho, et al.
Zeitschrift Fur Gastroenterologie|August 18, 2004
[Standard treatment of chronic hepatitis B]M P Manns, W H Caselmann, K H Wiedmann, et al.
Gastroenterology|October 26, 2001
Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse modelH Wedemeyer, S Gagneten, A Davis, et al.
Journal of Virology|November 2, 2001
Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cellsH Wedemeyer, E Mizukoshi, A R Davis, et al.
Zeitschrift Fur Gastroenterologie|July 17, 2009
Successful treatment of fulminant hepatitis B during pregnancyA Potthoff, K Rifai, H Wedemeyer, et al.
Deutsche Medizinische Wochenschrift (1946)|May 21, 2008
[Acute hepatitis B: is antiviral therapy indicated? Two case reports]J Girke, H Wedemeyer, J Wiegand, et al.
Zeitschrift Fur Gastroenterologie|June 14, 2003
[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3]M Cornberg, D Hüppe, J Wiegand, et al.
Pageof 16